TY - JOUR T1 - Are women leaders significantly better at controlling the contagion? JF - medRxiv DO - 10.1101/2020.06.06.20124487 SP - 2020.06.06.20124487 AU - Soumik Purkayastha AU - Maxwell Salvatore AU - Bhramar Mukherjee Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/12/2020.06.06.20124487.abstract N2 - Recent media articles have suggested that women-led countries are doing better in terms of their responses to the COVID-19 pandemic. We examine an ensemble of public health metrics to assess the control of COVID-19 epidemic in women- versus men-led countries worldwide based on data available up to June 3. The median of the distribution of median time-varying effective reproduction number for women- and men-led countries were 0.89 and 1.14 respectively with the 95% two-sample bootstrap-based confidence interval for the difference (women - men) being [- 0.34, 0.02]. In terms of scale of testing, the median percentage of population tested were 3.28% (women), 1.59% (men) [95% CI: (−1.29%, 3.60%)] with test positive rates of 2.69% (women) and 4.94% (men) respectively. It appears that though statistically not significant, countries led by women have an edge over countries led by men in terms of public health metrics for controlling the spread of the COVID-19 pandemic worldwide.One Sentence Summary We quantitatively compare countries led by women with countries led by men in terms of public health metrics for controlling the spread of the novel coronavirus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors will like to thank the University of Michigan Rogel Cancer Center, Center for Precision Health Data Science, University of Michigan School of Public Health and Michigan Institute of Data Science for supporting this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sourced from public repositories. All code are available at covind19.org. https://github.com/umich-cphds/cov-ind-19/blob/master/model/r_scripts/covind19_paper2.R https://github.com/umich-cphds/cov-ind-19/blob/master/model/r_scripts/covind19_paper2.R ER -